戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 acrophage homeostasis, lung inflammation and immunological disease.
2 screening, diagnosis, and treatment of human immunological disease.
3 CD8(+) T cells (Tc1) play important roles in immunological disease.
4 thways to CD39/adenosine-mediated effects in immunological disease.
5 ical pathway most significantly enriched was immunological disease.
6 the most common T-helper cell type 1 (T(H)1) immunological disease.
7 utility of antioxidants for the treatment of immunological disease.
8 correlated with the inflammatory response or immunological disease.
9 ospects for treating congenital and acquired immunological diseases.
10 rbation is causative of autoimmune and other immunological diseases.
11  in less-developed countries from developing immunological diseases.
12 cognize is an important task in the study of immunological diseases.
13 he mechanisms of the human immune system and immunological diseases.
14 rbors mutations underlying hematological and immunological diseases.
15  have implications in both proliferative and immunological diseases.
16 g make them attractive treatment targets for immunological diseases.
17 with the neurological, cancer, metabolic and immunological diseases.
18 nt target for the treatment of metabolic and immunological diseases.
19 eral human pathologies including cancers and immunological diseases.
20 ren and has been associated with a number of immunological diseases.
21 ing provided by the study of human monogenic immunological diseases.
22 of new methods to control hookworm and human immunological diseases.
23  serve as an important resource for studying immunological diseases.
24 been implicated in the pathology of multiple immunological diseases.
25  to novel therapeutic strategies for HIV and immunological diseases.
26 ntial therapeutic targets for infectious and immunological diseases.
27 ial alternative therapy for asthma and other immunological diseases.
28 elopment of novel therapeutic approaches for immunological diseases.
29 immune system and clinical efforts to assess immunological diseases.
30 ay be responsible for various autoimmune and immunological diseases.
31 concerning the mechanisms underlying several immunological diseases.
32  understanding of human immune responses and immunological diseases.
33 ted therapies for haematological cancers and immunological diseases.
34 ons were hematological disease and function, immunological disease and function, cancer, cell death,
35 ese studies reveal the effects of obesity on immunological disease and suggest a precision medicine a
36 anistic modeling to define new mechanisms of immunological disease and to accelerate the translation
37 e development of IL-2-based therapeutics for immunological diseases and cancer.
38 mune tolerance and play an important role in immunological diseases and cancers.
39 y combining genetic association in different immunological diseases and complementing functional anal
40 tions between genes and proteins involved in immunological diseases and processes are unknown.
41 mpare glucocorticoid sensitive and resistant immunological diseases and suggest that several aspects
42 controlling cellular movement, inflammation, immunological disease, and molecular transport.
43 , contributing to cancer, genetic disorders, immunological diseases, and developmental defects.
44 lineages, the connectivity between different immunological diseases, and the enrichment of cell subse
45 In particular, pathogenic Th17 cell-mediated immunological diseases appear to be effectively targeted
46 mmunologically naive mice and humans without immunological disease, as well as monoclonal IgM Abs to
47 ng potential candidates for the treatment of immunological diseases because of their immunosuppressiv
48 e cancer types, developmental disorders, and immunological diseases but current understanding of thei
49                    Classifying MAS using the immunological disease continuum model, with strict bound
50      Many patients present with the expanded immunological disease continuum that includes autoinflam
51 le cytokines has been associated with better immunological disease control and subsequent effectivene
52 enomic instability in cancer cells to enable immunological disease control.
53 anding of COVID-19, mechanistic insight into immunological, disease-driving factors remains limited.
54 that play a pivotal role in inflammatory and immunological diseases in the CNS.
55 ry disease' in MF mononuclear cells, and in 'immunological diseases' in MF granulocytes.
56 hown to have increased expression in several immunological diseases including asthma and allergic rhi
57 immune expressed SPs associate with numerous immunological diseases including Crohn's disease, multip
58 insight into the causal molecular drivers of immunological disease is a critical challenge in genomic
59  AIDS itself; that an emphasis on AIDS as an immunological disease is long overdue; and that appropri
60  developed countries have a low incidence of immunological diseases like inflammatory bowel disease (
61  and may protect their hosts from developing immunological diseases like inflammatory bowel disease.
62 ce unique is that they develop a spectrum of immunological diseases not seen in other agouti mutant m
63 ng place in context the changing patterns of immunological disease observed worldwide.
64 lar mechanisms of action in TNF-alpha driven immunological diseases, particularly autoimmune diseases
65  and delayed disease onset, whereas systemic immunological disease persisted.
66 ved regions across many traits, a very large immunological disease-specific enrichment of heritabilit
67                                              Immunological diseases such as inflammatory bowel diseas
68  that could be targeted for the treatment of immunological diseases that are characterized by insuffi
69 have opposite susceptibility to experimental immunological diseases, this suggests that the parallel
70 itional examples of the journey from unknown immunological diseases to new precision medicine treatme
71 rmation on both the pathogenesis of residual immunological disease under ART during pathogenic infect
72                                 Asthma is an immunological disease with multiple inflammatory and cli
73 f somatic mutations to complex and monogenic immunological diseases with a detailed review of unique
74 tudies successfully treated murine models of immunological diseases with miRNA-based approaches.
75 erve as molecular links between antibody and immunological disease, with FcgammaRIIA promoting tissue